To solve this problem, Siegwart and his team previously developed an advanced delivery strategy called selective organ targeting lipid nanoparticles (SORT LNP). 4 By modifying the composition and ...
ReCode, a clinical-stage genetic medicines company, has a solution to this challenge with their selective organ targeting (SORT) LNP platform technology that enables delivery of a wide range of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback